Accessibility Menu
Adaptive Biotechnologies logo

Adaptive Biotechnologies(NASDAQ) ADPT

Market Cap$4.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-38%
5 Year-22%
1 Year+109%
1 Month+21%
$25.47
+2.17%
+0.54Today
After hours$25.47+$0.00 (+0.00%)
Adaptive Biotechnologies last closing stock price
MetricPriceDate
Last closeUSD 25.452026-08-10
Adaptive Biotechnologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10.13%USD 23.112026-08-03
1 month+20.85%USD 21.062026-07-10
3 month+86.72%USD 13.632026-05-12
Year to date+56.71%USD 16.242025-12-31
1 year+108.61%USD 12.202025-08-08
3 year+303.97%USD 6.302023-08-11
5 year-22.08%USD 32.662021-08-11
Since inception-38.14%USD 40.302019-06-27

Adaptive Biotechnologies Financials at a Glance

Market Cap

$4.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$308.08M

Net Income (TTM)

-$63.85M

EPS (TTM)

-$0.41

P/E Ratio

-62.39

Dividend

$0.00

Beta (Volatility)

2.03 (High)

Price

$25.47

Volume

23

Open

$24.90

Previous Close

$25.45

Daily Range

$24.65 - $26.16

52-Week Range

$11.92 - $26.16

Estimated Earnings Date

Nov 4, 2026

ADPT News

SellAlert-Purple.png

An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run

Jonathan PoncianoJul 12, 2026
SellAlert-Blue.png

What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?

Robert IzquierdoJun 14, 2026
SellAlert-Red.png

Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million

Cory RenauerMay 26, 2026
SellAlert-Red.png

Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors.

Robert IzquierdoMay 4, 2026
SellAlert-Red.png

Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means

Seena HassounaApr 20, 2026
SellAlert-Blue.png

Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?

Cory RenauerApr 18, 2026
SellAlert-Green.png

Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On

Jonathan PoncianoApr 8, 2026
SellAlert-Purple.png

Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look

Seena HassounaMar 30, 2026
Page 1

ADPT: Motley Fool Moneyball Superscore

75

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Adaptive Biotechnologies

Adaptive helps doctors read the human immune system. Its technology translates genetic codes into data for treating disease. This helps medical teams find and monitor cancer or other illnesses.

Decoding the Immune System

  • Minimal Residual Disease: Diagnostic tests that detect tiny amounts of cancer cells; generated $67.1 million in revenue in the first quarter of 2026.
  • Immune Medicine: Research tools helping scientists understand how the body fights disease; contributed $3.8 million in revenue in the first quarter of 2026.
  • clonoSEQ: Clinical test authorized by the Food and Drug Administration to monitor specific blood cancers in patients.
  • immunoSEQ: Research platform used by scientists to find new diagnostic signals in human blood.

Partners and New Paths

  • Collaborated with Genentech on cancer therapies until the formal agreement ended in February 2026.
  • Partnered with Microsoft to develop blood tests that detect multiple diseases using a single sample.
  • Expanded clonoSEQ coverage in April 2025 to monitor recurrence in patients with certain white blood cell cancers.
  • Earned $9 million in milestone payments from drug-making partners during the first quarter of 2026.

What Makes Adaptive Different?

Adaptive uses machine learning to map immune receptors to specific diseases at high speed. This platform converts biological signals into a digital database used for drug development and patient care.

Scaling the Numbers

  • Total revenue reached $70.9 million in Q1 2026, up 35.1% from the same period in 2025.
  • Net loss narrowed to $20.0 million in Q1 2026, an improvement of 32.9% year-over-year.
  • Gross profit rose to $52.2 million in Q1 2026, up 47.1% from $35.5 million in Q1 2025.
  • Free cash flow improved by 65.3% to a loss of $10.3 million in Q1 2026.

Bottom Line

Adaptive has evolved from a research firm into a clinical provider of cancer monitoring tools. The company is reducing its losses while expanding the use of its specialized immune-sequencing technology.

AI Generated • May 26, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

624

CEO

Chad Robins, MBA

Website

www.adaptivebiotech.com

Headquarters

Seattle, WA 98109, US

ADPT Financials

Key Financial Metrics (TTM)

Gross Margin

75.44%

Operating Margin

-12.16%

Net Income Margin

-20.73%

Return on Equity

-32.64%

Return on Capital

-11.44%

Return on Assets

-9.97%

Earnings Yield

-1.60%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

159.60M

Volume

23

Avg. Volume

2.87M

Financials (TTM)

Gross Profit

$232.40M

Operating Income

-$37.46M

EBITDA

-$15.96M

Operating Cash Flow

-$21.01M

Capital Expenditure

-$3.03M

Free Cash Flow

-$24.03M

Cash & ST Invst.

$344.26M

Total Debt

$410.50M

Adaptive Biotechnologies Performance Analysis

Adaptive Biotechnologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 185,308,00020.1%
20232023-12-31USD 170,276,000-8.1%
20242024-12-31USD 178,957,0005.1%
20252025-12-31USD 276,976,00054.8%
Adaptive Biotechnologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3059.6%
Q42025-12-31-23.7%
Q12026-03-31-1.1%
Q22026-06-301.0%
Adaptive Biotechnologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.40-4.9%
20232023-12-31USD -1.5611.1%
20242024-12-31USD -1.08-30.5%
20252025-12-31USD -0.39-63.8%
Adaptive Biotechnologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30134.4%
Q42025-12-31-253.8%
Q12026-03-31-44.4%
Q22026-06-30-92.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$71.55M

+21.5%

Gross Profit

$50.97M

+24.7%

Gross Margin

71.23%

N/A

Market Cap

$4.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.51M

N/A

Employees

624

N/A

Net Income

-$39.79M

-55.3%

EBITDA

-$12.08M

+33.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$344.26M

+74.0%

Total Debt

$410.50M

+386.5%

Accounts Receivable

$49.51M

+11.8%

Inventory

$10.50M

+24.9%

Long Term Debt

$401.68M

+439.8%

Short Term Debt

$8.82M

-11.4%

Return on Assets

-9.97%

N/A

Return on Invested Capital

-6.77%

N/A

Free Cash Flow

-$7.58M

+42.0%

Operating Cash Flow

-$6.40M

+48.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CPRXCatalyst Pharmaceuticals, Inc.
$31.49+0.00%
LEGNLegend Biotech Corporation
$20.66-0.43%
IDYAIDEAYA Biosciences, Inc.
$36.74-0.76%
IRONDisc Medicine, Inc.
$78.28+1.08%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$73.80-0.01%
INTCIntel
$97.52-0.04%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$37.73+0.01%
SPCXSpace Exploration Technologies
$138.74+0.04%

Questions About ADPT

What is the current price of Adaptive Biotechnologies?

Adaptive Biotechnologies is trading at $25.45 per share.

What is the 52-week range for Adaptive Biotechnologies?

Over the past 52 weeks, Adaptive Biotechnologies has traded between $11.92 and $26.16.

How much debt does Adaptive Biotechnologies have?

As of the most recent reporting period, Adaptive Biotechnologies reported total debt of $410.50M.

How much cash does Adaptive Biotechnologies have on hand?

Adaptive Biotechnologies reported $169.87M in cash and cash equivalents in its most recent financial results.

What is Adaptive Biotechnologies’s dividend yield?

Adaptive Biotechnologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services